• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia
CONCLUSION: In CLL patients, pneumococcal revaccination induced minor early plasmablast response compared to controls, but the response improved using a strategy of repeated doses with of conjugated T cell dependent pneumococcal vaccine.PMID:37061372 | DOI:10.1016/j.vaccine.2023.04.016
Source: Vaccine - April 15, 2023 Category: Allergy & Immunology Authors: Magdalena K ättström Bertil Uggla Elisabet Tina Eva Kimby Torbj örn Norén Simon Athlin Source Type: research

Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome
CONCLUSIONS: Acute lymphoblastic leukemia, vaccines against hepatitis A and meningococci can be included among antecedent factors in OMAS. Among clinical symptoms, speech problems might point to the likelihood of an underlying neoplasm in OMAS. Intravenous immunoglobulin and steroids may be chosen for initial treatment while rituximab can increase the chance of recovery in case of persistent or recurrent symptoms. The presence of relapse was associated with poor outcome.PMID:36155293 | DOI:10.1016/j.ejpn.2022.09.002
Source: European Journal of Paediatric Neurology - September 26, 2022 Category: Neurology Authors: Mira ç Yıldırım İbrahim Öncel Ömer Bektaş Gizem Tanal ı S üleyman Şahin Tezer Kutluk Serap Teber Banu Anlar Source Type: research

Vaccines for measles, mumps, rubella, and varicella in children
CONCLUSIONS: Existing evidence on the safety and effectiveness of MMR/MMRV vaccines support their use for mass immunisation. Campaigns aimed at global eradication should assess epidemiological and socioeconomic situations of the countries as well as the capacity to achieve high vaccination coverage. More evidence is needed to assess whether the protective effect of MMR/MMRV could wane with time since immunisation.PMID:34806766 | DOI:10.1002/14651858.CD004407.pub5
Source: Cochrane Database of Systematic Reviews - November 22, 2021 Category: General Medicine Authors: Carlo Di Pietrantonj Alessandro Rivetti Pasquale Marchione Maria Grazia Debalini Vittorio Demicheli Source Type: research

Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?
CONCLUSION: Despite vaccination opportunities, the complexity of these specific recommendations and the lack of communication between the health actors could explain the suboptimal vaccination coverage in this high-risk population. A proactive attitude of all actors in the city and hospital, including better patient information and a personalized and evolving vaccination schedule to help GPs to coordinate vaccination would allow to improve vaccine coverage.PMID:34740475 | DOI:10.1016/j.vaccine.2021.10.040
Source: Vaccine - November 6, 2021 Category: Allergy & Immunology Authors: Alix Pierron Fabienne Bozon Ana Berceanu Jean Fontan Annie Brion Erick Deconinck Catherine Chirouze Anne-Sophie Brunel Source Type: research

Vaccines for measles, mumps, rubella, and varicella in children.
CONCLUSIONS: Existing evidence on the safety and effectiveness of MMR/MMRV vaccines support their use for mass immunisation. Campaigns aimed at global eradication should assess epidemiological and socioeconomic situations of the countries as well as the capacity to achieve high vaccination coverage. More evidence is needed to assess whether the protective effect of MMR/MMRV could wane with time since immunisation. PMID: 32309885 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - April 19, 2020 Category: General Medicine Authors: Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V Tags: Cochrane Database Syst Rev Source Type: research

Pages: 1  2